Other Mutations: TSC

NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1)

NCT05103358
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TSC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases: 
Additional Notes: Patients must have tumors that express a TSC1 or TSC2 alteration
Exclusions: Patients with prior treatment of an mTOR inhibitor, including nab-sirolimus; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05103358

NCT04185831: A Molecularly Guided Anti-Cancer Drug Off-Label Trial

NCT04185831
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NF1/2, MAPK, mTOR, TSC, TMB-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active progressive CNS metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04185831

Up ↑